Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.41 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | ARG1 | P05089 | 1/20 | 0.40 |
| ▸ | ARG2 | P78540 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2622478 | 0.89 | ARG1 (0.47) | S1PR1S1PR3TDP1L3MBTL1TNNC1 | |
| SCHEMBL14499316 | 0.84 | GRM2 (0.50) | S1PR1S1PR3FFAR1TDP1ARG1 | |
| SCHEMBL13932736 | 0.81 | S1PR1 (0.66) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| SCHEMBL13953244 | 0.77 | ARG1 (0.36) | FFAR1ARG1ARG2NPC1RAB9A | |
| SCHEMBL904106 | 0.77 | S1PR1 (0.64) | S1PR1S1PR3CYP1A2CYP2A6TAAR1 | |
| SCHEMBL14769843 | 0.76 | S1PR1 (0.38) | S1PR1S1PR3TNNC1SGPL1S1PR4 | |
| SCHEMBL15496714 | 0.75 | PPARA (0.48) | FFAR1TDP1L3MBTL1CYP1A2CYP2A6 | |
| SCHEMBL15326074 | 0.75 | SMN1; SMN2 (0.47) | FFAR1TDP1L3MBTL1CYP1A2CYP2A6 | |
| SCHEMBL13614227 | 0.75 | CYP1A2 (0.47) | S1PR1S1PR3CYP1A2CYP2A6TAAR1 | |
| SCHEMBL2632242 | 0.75 | S1PR1 (0.67) | S1PR1S1PR3TNNC1SGPL1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757407-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | UNIV PRINCETON (US) | 2016-12-01 | — | — | US | disclosed |
| US-9029413-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| US-20070135450-A1 | Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy | FORBES MEDI-TECH (RESEARCH), INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | S1PR1 980/4885S1PR3 1425/4885FFAR1 2747/4885 |
| US-20160346309-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | S1PR1 980/4885S1PR3 1425/4885FFAR1 2747/4885 |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | S1PR1 980/4885S1PR3 1425/4885FFAR1 2747/4885 |
| US-20070135450-A1 | Compounds and Methods of Treating Insulin Resistance and Cardiomyopathy | CPT1A, CPT1B, PNLIP | S1PR1 161/4885S1PR3 282/4885FFAR1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.